COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess-Reference-Cited by-同舟云学术

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess

Published:2020-08 Issue:8 Volume:8 Page:654-656
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Pivonello Rosario,Ferrigno Rosario,Isidori Andrea M,Biller Beverly M K,Grossman Ashley B,Colao Annamaria

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference10 articles.

1. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19);Kakodkar;Cureus,2020

2. Complications of Cushing's syndrome: state of the art;Pivonello;Lancet Diabetes Endocrinol,2016

3. Immune regulation by glucocorticoids;Cain;Nat Rev Immunol,2017

4. The immune system in Cushing's syndrome;Hasenmajer;Trends Endocrinol Metab,2020

5. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19;Ye;J Infect,2020

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of the COVID Pandemic on Adrenal Surgery at an Academic Endocrine Surgery Unit;Hormone and Metabolic Research;2023-10-30

2. COVID-19 infection in a patient with Cushing’s disease on osilodrostat treatment;Endokrynologia Polska;2023-06-26

3. COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma;ENDOCR DIAB MET C R;2023

4. Endocrine and metabolic complications of COVID-19: lessons learned and future prospects;Journal of Molecular Endocrinology;2022-10-01

5. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples;Pituitary;2022-08-24